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Acyl-CoA thioesterase-1 
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of 2-APA-CoA esters. The 
results suggest ACOT-1 
plays a key role in the chiral 
inversion of ibuprofen and 
other 2-APA drugs. 
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Abstract 
Ibuprofen and related 2-arylpropanoic acid (2-APA) drugs are often given as a racemic mixture and 
the R-enantiomers undergo activation in vivo by metabolic chiral inversion. The chiral inversion 
pathway consists of conversion of the drug to the coenzyme A ester (by an acyl-CoA synthetase) 
followed by chiral inversion by α-methylacyl-CoA racemase (AMACR; P504S). The enzymes 
responsible for hydrolysis of the product S-2-APA-CoA ester to the active S-2-APA drug have not 
been identified. In this study, conversion of a variety of 2-APA-CoA esters by human acyl-CoA 
thioesterase-1 and -2 (ACOT-1 and -2) was investigated. Human recombinant ACOT-1 and -2 
(ACOT-1 and -2) were both able to efficiently hydrolyse a variety of 2-APA-CoA substrates. 
Studies with the model substrates R- and S-2-methylmyristoyl-CoA showed that both enzymes were 
able to efficiently hydrolyse both of the epimeric substrates with (2R)- and (2S)- methyl groups. 
ACOT-1 is located in the cytosol and is able to hydrolyse 2-APA-CoA esters exported from the 
mitochondria and peroxisomes for inhibition of cyclo-oxygenase-1 and -2 in the endoplasmic 
reticulum. It is a prime candidate to be the enzyme responsible for the pharmacological action of 
chiral inverted drugs. ACOT-2 activity may be important in 2-APA toxicity effects and for the 
regulation of mitochondrial free coenzyme A levels. These results support the idea that 2-APA 
drugs undergo chiral inversion via a common pathway.  
  
1. Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in both human and veterinary 
medicine. Important examples of NSAIDs include aspirin, indomethacin, diclofenac and ibuprofen. 
Ibuprofen is a member of the 2-arylpropanoic acid (2-APA; a.k.a. profens) group of drugs, and it is 
probably the most widely used non-prescription drug. The accepted pharmacological targets of 
ibuprofen, cyclo-oxygenases-1 and -2 (COX-1 and -2), are potently inhibited by its S-enantiomer, 
whilst the R-enantiomer is much less effective [1]. In vivo the R-enantiomer of ibuprofen undergoes 
rapid uni-directional conversion into the S-enantiomer [2, 3], a metabolic process known as chiral 
inversion. Consequently, R-ibuprofen is activated as an inhibitor of COX-1 and -2. 
The chiral inversion pathway (Figure 1) consists of three phases: 1) Stereoselective conversion of 
the R-ibuprofen 1R to R-ibuprofenoyl-CoA 2R by long-chain acyl-CoA synthetase [4-6] via an 
acyl-adenylate intermediate [7]; 2) Conversion of the R-ibuprofenoyl-CoA 2R into a ca. 1:1 mixture 
of R- and S-ibuprofenoyl-CoA 2R/2S by α-methylacyl-CoA racemase [8-10] (ibuprofenoyl-CoA 
epimerase [11, 12]); and 3) Hydrolysis of both ibuprofenoyl-CoA epimers 2 [13] to a racemic 
mixture of ibuprofen 1 by an undefined acyl-CoA thioesterase (ACOT). Product R-ibuprofen 1R is 
reconverted back to its acyl-CoA ester, whilst S-ibuprofen 1S is not recycled and this accounts for 
the overall uni-directional R  S chiral inversion of the pathway. Most other 2-APA drugs also 
undergo in vivo chiral inversion in humans (reviewed in [8]), and α-methylacyl-CoA racemase has 
been shown to accept several other 2-APA-CoA esters as substrates [9]. 
Microsomal [14] long-chain fatty acyl-CoA synthetase (ibuprofenoyl-CoA synthetase [4]) produces 
R-2-APA-CoA esters which are imported into mitochondria and peroxisomes (probably via the 
acyl-carnitine shuttle [15]), for chiral inversion by α-methylacyl-CoA racemase [16-18]. Cyclo-
oxygenase-1 and -2 (a.k.a. prostaglandin E2 synthetase or endoperoxidase) [1, 19] are located in the 
endoplasmic reticulum [20, 21], implying that S-2-APA-CoA esters must be exported (via a reverse 
carnitine shuttle [22]) to interact with the target. Hydrolysis of 2-APA-CoA esters within 
mitochondria has also been linked to 2-APA toxicity [23, 24]. Humans contain a large number of 
ACOT enzymes [25-27], with ACOT-1 localised in the cytosol and ACOT-2 localised in 
mitochondria [27]. This paper reports a study on the possible roles of human ACOT-1 and ACOT-2 
in the 2-APA chiral inversion pathway.  
 
2. Materials and Methods 
2.1. Sources of materials: 
All chemicals were obtained from the Sigma-Aldrich Chemical Co. or Fisher Scientific Ltd and 
were used without further purification, unless otherwise noted. Aqueous solutions were made in 
18.2 Mega-Ω.cm Milli-Q water and pH adjusted with HCl or NaOH solutions as appropriate. KOD 
polymerase, the pET46 vector system, competent cells, Bugbuster, and Benzonase were obtained 
from Novagen. IPTG was from Calbiochem. Dpn1 was from New England Biolabs. Primers and 
protein molecular weight markers were from Invitrogen. Plasmids were obtained from imaGenes 
Gmbh, Germany (http://www.lifesciences.sourcebioscience.com/; ACOT-1: IRCMp5012A0824D; 
Hs.568046; ACOT-2: IRAUp969B0534D; Hs.649479). The syntheses of myristoyl-CoA 3 and R- 
and S-2-methylmyristoyl-CoA, 4R and 4S, are described in Supplementary Information available 
from the corresponding author. ±-Fenoprofenoyl-CoA 5, ±-flurbiprofenoyl-CoA 6, ±-ibuprofenoyl-
CoA 2, S-ketoprofenoyl-CoA 11 and S-naproxenoyl-CoA 12 were synthesised as previously 
described [9]. 
2.3. Sub-cloning of human ACOT-1 and -2: 
ACOT-1 was amplified using the following primers: forward, 
GACGACGACAAGATGGCGGCGACGCTGAT; reverse, GAGGAGAAGCCCGGTTA 
CACTTTTGATGGGATTGTCCC. ACOT-2 was amplified using the following primers: forward, 
GACGACGACAAGATGTCTAACAAGCTTCTTTCTCCCCA; reverse, 
GAGGAGAAGCCCGGTTACACTTTTGATGGGATTGTCCC. PCR reactions contained the 
following: plasmid template (1 L; 100 ng); primers (2 x 3 L; 5 M each); buffer (5 L); dNTPs 
(5 L); MgSO4 (2 L); KOD polymerase (1 L, 2.5 activity units); and sterile water (30 L). 
Reactions were amplified by the following procedure: 94 ºC, 2 min; 35 cycles of: 94 ºC, 15 s; 52 ºC, 
30s; 68 ºC, 2 min; followed by 72 ºC, 2 min. The reaction products were treated with dpn1 (2 L, 
40 activity units) for 2 h at 37 ºC to remove template DNA, and the presence of the amplified DNA 
confirmed by 1% agarose gel electrophoresis. The PCR product was purified using a QIAquick 
PCR purification kit (Qiagen) and quantified (GeneQuant). The product was inserted into the 
pET46 vector according to the manufacturers’ instructions and transformed into Giga cells. Single 
colonies were selected, grown in 5 mL Lennox LB media supplemented with ampicillin (50 g/mL) 
and plasmids prepared. The presence of the required insert in the plasmid was confirmed by PCR 
analysis using 1 L template in a final volume of 20 L followed by 1% (w/v) agarose gel 
electrophoresis. DNA sequencing confirmed the sequence of ACOT-1 was identical to A1L172 
(http://www.uniprot.org). The sequence of ACOT-2 was identical to P49753 with the known 
A454V polymorphism. 
 
2.4. Expression and purification of ACOT enzymes 
Expression plasmids were transformed into E. coli BL21 (DE3) pLysS [28] and grown in Lennox 
LB media supplemented with ampicillin (50 g/mL) and chloramphenicol (32 g/mL) at 37 ºC and 
190 r.p.m. Starter culture (30 mL) was used to inoculate 1L of the same media, grown under the 
same conditions until OD600 = ~1.5 and induced with 1 mM IPTG. Cells were harvested after 3 
hours by centrifugation (JA-10 rotor, 9,000 r.p.m., 14 300 g, 20 min., 4 ºC) and stored at -80 ºC. 
 
Cells (ca. 5 g) were lysed using 30 mL Bugbuster supplemented with 250 u Benzonase at 4 ºC, 
followed by centrifugation [28]. The crude extract was filtered and loaded onto a 5 mL HisTrap FF 
Ni
2+
 column equilibrated in 20 mM NaH2PO4-NaOH, 300 mM NaCl, 10 mM imidazole, pH 7.2. 
The column was washed with 10 mL buffer and eluted with 300 mM imidazole-HCl, pH 7.2 in the 
same buffer. Fractions (5 mL) were analysed by 10% SDS-PAGE, and those containing ACOTs 
were pooled and dialysed against 20 mM HEPES-NaOH, pH 7.27 (3 x 650 mL). Protein 
concentrations were determined using absorbance at 280 nm with parameters calculated with 
protparam (http://web.expasy.org/protparam/) for the His-tag enzyme: ACOT-1; Mw = 48 009.1 
Da.,  = 48 360 M
-1
 cm
-1
; ACOT-2; Mw = 54 978.3 Da.,  = 55 350 M
-1
 cm
-1
. 
 
2.5. ACOT assays 
Assays were conducted in 50 mM HEPES-NaOH, pH 7.27 in a final volume of 100 L at 25 ºC. 
Rates at each substrate concentration were measured using three dependent repeats. Reactions were 
carried out at pH 7.27, as this minimizes spontaneous hydrolysis of DTNB [29]. Assay mixtures 
contained substrate at the required concentration, DTNB (100 M) and enzyme (50-75 g). 
Myristoyl-CoA 3 and R- and S-2-methylmyristoyl-CoA (4R and 4S) were pre-incubated with BSA 
at a constant ratio [substrate: BSA (100: 2.88 M)] for 10 minutes before assaying. Assays using 2-
APA-CoA substrates did not contain BSA. Reaction rates were obtained by plotting changes in 
absorbance with Excel. Activities in nmol.min.
-1
mg
-1
 were calculated assuming ε412 = 14.15 mM
-1
 
cm
-1
 at 25 ºC [29, 30], and kinetic parameters obtained using the Direct Linear Plot [31, 32] in 
SigmaPlot 11 and enzyme kinetics module 1.3. Kinetic plots for all substrates are available in 
Supplementary Information, available from the corresponding author. 
 
2.6. Structural models of ACOT-2 
Models were produced based on the X-ray crystal structure of human ACOT-2 determined without 
any substrate [32]. The binding pocket was identified based on the proximity to the active site 
residues Ser-294, Asp-388 and His-422. Once docked, the 2-APA-CoAs were subjected to 
molecular mechanics and dynamics calculations to establish optimal docking conformations; during 
these calculations, the enzyme and coenzyme A moiety were restrained to original conformations. 
The 2-APA-CoA and binding pocket were subjected to molecular dynamics and finally molecular 
mechanics calculations to give the final structures. Calculations were performed using the Tripos 
Associates force fields within the SYBYL-X 2.0 software suite on a dual Intel quad core 
workstation (Windows 7). Gasteiger-Hückel charges were calculated and used within the 
complexes. 
 
3. Results 
Recombinant human ACOT-1 and ACOT-2 were produced with an N-terminal His-tag sequence 
and purified by metal-chelate chromatography. The 2-APA-CoA esters which had previously been 
shown to be substrates for α-methylacyl-CoA racemase [9] were synthesised for testing as 
substrates (Figure 2). R- and S-2-methylmyristoyl-CoA (4R and 4S) were synthesised by 
modification of the route for R- and S-2-methyldecanoyl-CoA [33] to investigate the effect of the 2-
methyl group epimeric configuration on substrate conversion. Myristoyl-CoA 3 was synthesised as 
a known good substrate of ACOT-1 and ACOT-2 [28]. 
The conversion of acyl-CoA esters to their corresponding acids and reduced coenzyme A by 
ACOT-1 and -2 was assessed using the reported assay with DTNB [28]. All of the tested acyl-CoA 
esters were efficiently converted to products (Tables 1 and 2). Myristoyl-CoA 3, R-2-
methylmyristoyl-CoA 4R and S-2-methylmyristoyl-CoA 4S showed Michaelis-Menten behaviour 
as substrates for ACOT-1 and ACOT-2. In the case of ACOT-1 (Table 1) a Km value of 39 µM was 
determined for myristoyl-CoA 3, compared to 9.3 and 12 µM for 2-methylmyristoyl-CoA 4R and 
4S, respectively. Catalytic efficiency (as measured by kcat/Km) was determined to be 151 M
-1
 s
-1 
for 
myristoyl-CoA 3, 128 M
-1
 s
-1
 for R-2-methylmyristoyl-CoA 4R and 230 M
-1
 s
-1
 for S-2-
methylmyristoyl-CoA 4S, showing that the 2S- substrate was somewhat preferred. In the case of 
ACOT-2 (Table 2), R-2-methylmyristoyl-CoA 4R was converted most efficiently (as judged by 
kcat/Km), followed by myristoyl-CoA 3 and S-2-methylmyristoyl-CoA 4S. Thus, both ACOT 
enzymes show some preference for particular epimeric configurations of the 2-methylmyristoyl-
CoA substrate 4. 
Hydrolysis of 2-APA-CoA esters to their corresponding acids by ACOT-1 and ACOT-2 was 
then investigated, and all of the tested 2-APA-CoAs were good substrates (Tables 1 & 2) and 
proper Michaelis-Menten kinetics were observed. In the case of ACOT-1 (Table 1) most 
substrates, including ibuprofenoyl-CoA (Figure 3), were converted with similar efficiencies 
(kcat/Km = 140-220 M
-1
 s
-1
), except for S-ketoprofenoyl-CoA 7S (kcat/Km = 45 M
-1
 s
-1
). This 
shows that ACOT-1 has a broad substrate selectivity. In the case of ACOT-2 (Table 2), the best 
2-APA-CoA substrates were ±-fenoprofenoyl-CoA 5 and ±-flurbiprofenoyl-CoA 6 (kcat/Km = ca. 
320 M
-1
 s
-1
), followed by S-naproxenoyl-CoA 8 (kcat/Km = 249 M
-1
 s
-1
), S-ketoprofenoyl-CoA 7 
(kcat/Km = 145 M
-1
 s
-1
) and ±-ibuprofenoyl-CoA 2 (kcat/Km = 70 M
-1
 s
-1
). Thus, ACOT-2 showed 
a somewhat higher variability in substrate conversion efficiency, with the best substrates been 
converted somewhat more efficiently than by ACOT-1 (kcat/Km = 346 cf 230 s
-1
 M
-1
). 
The substrate selectivity of ACOT-1 and -2 was further investigated by a substrate docking study 
(Figure 4) starting from the crystal structure of the ACOT-2 enzyme without any substrate bound 
[32]. ACOT-1 and ACOT-2 have almost identical core amino acid sequences, and hence are 
expected to possess similar substrate selectivities. The binding position of the acyl-CoA moiety was 
established by proximity to Ser-294, His-422 and Asp-388, the catalytic triad which performs the 
hydrolysis reaction. Two small pockets accommodate the methyl groups of 2R- and 2S- substrates, 
explaining how both epimers of 2-methyl substrates can be hydrolysed and the preference for 
branched-chain acyl-CoA esters over straight-chain acyl-CoA esters. The aromatic side-chain 
common to all 2-APA drugs projects into a deep lipophilic pocket, forming transient π stacking 
interactions with the side-chain of Trp-391. This lipophilic pocket also accommodates the various 
substituents on the aromatic ring in the various 2-APA drugs. The phosphopantetheinyl- side-chain 
of the CoA moiety is enclosed within a narrow tunnel lined with acidic and basic residues. Several 
possible sites were available for the 3-phospho-adenosine moiety, and modelling studies proved 
inconclusive with multiple binding configurations with similar energies observed.  
 
4. Discussion 
Humans contain a large number of ACOT enzymes [25-28, 34], and ACOTs -1, -2, -4 and -8 were 
identified as potentially been able to hydrolyse substrates possessing 2-methyl groups based on 
previous work. ACOT-1 was selected for further study since it was potentially able to hydrolyse 
inverted 2-APA-CoA esters exported from mitochondria and peroxisomes into the cytosol. ACOT-2 
was also selected for further study as it is localised in mitochondria, and can potentially hydrolyse 
2-APA-CoA esters imported via the acyl-carnitine shuttle and hence potentially contribute to 2-
APA-mediated toxicity mechanisms [23]. ACOT-1 and ACOT-2 are both type I enzymes and share 
very high sequence identity within their core regions [34]; ACOT-2 mainly differs in that it 
possesses a N-terminal mitochondrial targeting signal which is absent in ACOT-1 (Supplementary 
Information, Figure S1). 
Both ACOT-1 and ACOT-2 show limited discrimination between different chiral configurations of 
the substrate, as demonstrated by conversion of both R- and S-2-methylmyristoyl-CoA (4R and 4S). 
The results are consistent with the previous observations that both epimers of ibuprofenoyl-CoA 
[13] and fenoprofenoyl-CoA [35] can be hydrolysed in the chiral inversion pathway. The broad 
substrate selectivity of ACOT-1 and ACOT-2 is similar to that observed for α-methylacyl-CoA 
racemase [9], and is consistent with a common chiral inversion pathway existing for all 2-APA 
drugs undergoing chiral inversion. The observed uni-directional R  S chiral inversion in vivo is 
due to stereoselective formation of R-2-APA-CoA esters by long-chain fatty acyl-CoA synthetase 
[4-6].  R-Flurbiprofen does not undergo chiral inversion in humans, although it does in other 
mammalian species [36, 37], despite  ±-flurbiprofenoyl-CoA 6 been a substrate for both AMACR 
[9] and ACOTs. Studies on purified long-chain fatty acyl-CoA synthetase [4] have shown that R-
Flurbiprofen is not converted to R-flurbiprofenoyl-CoA 6R. It therefore seems likely that the failure 
of flurbiprofen to undergo chiral inversion in humans is due to non-formation of the acyl-CoA ester 
in vivo [8, 9].   
The results in this paper show that both ACOT-1 and ACOT-2 possess broad substrate selectivity. 
Modelling studies (Figure 4) support the roles of the proposed catalytic residues [38] and explain 
how the enzyme is able to accommodate straight-chain and both epimeric configurations of 2-
methyl substrates. Branched-chain substrates are slightly preferred (based on kcat/Km values), 
presumably due to accommodation of the 2-methyl group within their binding pockets and this is 
consistent with other enzymes that metabolise branched-chain acyl-CoA substrates [39]. The π 
stacking interactions with the side-chain of Trp-391 explains the favourable binding of 2-APA-CoA 
esters, and the lipophilic binding pocket the tolerance for diverse side-chain structures. The 
situation is reminiscent of that observed for AMACR [9], the enzyme catalysing the chiral inversion 
step in the metabolic pathway, in which broad substrate selectivity is achieved by non-specific 
hydrophobic interactions with a methionine-rich surface. Some 2-APA-CoA substrates are 
converted much less efficiently by ACOT-1 or ACOT-2 than most substrates, most notably S-
ketoprofenoyl-CoA 7S (ACOT-1) and ±-ibuprofenoyl-CoA 2 (ACOT-2). The reasons why these 
substrates are converted less efficiently are unclear. 
In summary, 2-APA-CoA esters are good substrates for both ACOT-1 and ACOT-2. These 
enzymes appear to play a central role in the chiral inversion pathway of 2-APA drugs, catalysing 
the third step in the pathway. The results also support a common chiral inversion pathway for all 2-
APA drugs.  
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 Figure 1: The chiral inversion pathway of 2-APA drugs, using ibuprofen 1 as an example. 
 
 
 
Figure 2: Acyl-CoA esters tested as substrates with human ACOT-1 and -2. 
  
 Substrate Km (M) Vmax (nmol. 
min.
-1
mg
-1
) 
kcat (s
-1
) kcat/Km 
(s
-1
 M
-1
)
 
Myristoyl-CoA 3 39 7.40 0.0059 151 
R-2-Methylmyristoyl-CoA 4R 9.3 1.48 0.0012 128 
S-2-Methylmyristoyl-CoA 4S 12 3.37 0.0027 230 
±-Fenoprofenoyl-CoA 5 32 6.89 0.0055 173 
±-Flurbiprofenoyl-CoA 6 18 5.07 0.0040 218 
±-Ibuprofenoyl-CoA 2 7.0 1.63 0.0013 186 
S-Ketoprofenoyl-CoA 7S 11 0.62 0.0004 45 
S-Naproxenoyl-CoA 8S 3.0 0.52 0.0004 141 
 
Table 1: Kinetic parameters determined for human ACOT-1. Reported values are medians obtained 
from the Direct Linear Plot. 
 
  
Substrate Km (M) Vmax (nmol. 
min.
-1
mg
-1
) 
kcat (s
-1
) kcat/Km 
(s
-1
 M
-1
)
 
Myristoyl-CoA 3 14.9 3.1 0.0028 192 
R-2-Methylmyristoyl-CoA 4R 2.75 1.0 0.0009 346 
S-2-Methylmyristoyl-CoA 4S 35.1 5.9 0.0054 155 
±-Fenoprofenoyl-CoA 5 21.2 7.5 0.0069 326 
±-Flurbiprofenoyl-CoA 6 25.5 8.7 0.0079 312 
±-Ibuprofenoyl-CoA 2 121 9.2 0.0084 70 
S-Ketoprofenoyl-CoA 7S 3.65 0.57 0.0005 145 
S-Naproxenoyl-CoA 8S 2.04 0.55 0.0005 249 
  
Table 2: Kinetic parameters determined for human ACOT-2. Reported values are medians obtained 
from the Direct Linear Plot. 
 
  
 A. 
 
B. 
 
Figure 3: Kinetic plots of ibuprofenoyl-CoA hydrolysis catalysed by ACOT-1. A. Direct Linear 
Plot; B. Michaelis-Menten plot. Error bars are ± standard error (± SE). 
  
Figure 4: S-ibuprofenoyl-CoA bound into the ACOT2 binding pocket [32]. Ser-294 is located in 
the base of the pocket in close proximity to the carbonyl group of the thioester; His-422 and Asp-
388 are located deeper within the enzyme. The exact orientation of the 3-phosphoadenosine moiety 
could not be established with several possible binding channels available.  
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Synthetic route to substrates 
R-2-Methylmyristoyl-CoA 4R and S-2-methylmyristoyl-CoA 4S were synthesized by the same 
route as for S-2-methyldecanoyl-CoA and R-2-methyldecanoyl-CoA [40] (Scheme S1). Myristoyl-
CoA 3 was synthesized by the reaction of myristic acid 9 (tetradecanoic acid) with carbonyl di-
imidazole followed by coenzyme A. 2-APA-CoA esters were synthesized as previously described 
[9]. 
 
 
Scheme S1: Synthesis of substrates: A) Myristoyl-CoA 3; B) R-2-methylmyristoyl-CoA 4R; C) S-2-
methylmyristoyl-CoA 4S;  
 
General experimental 
All chemicals were obtained from the Sigma-Aldrich Chemical Co. or Fisher Scientific Ltd and 
were used without further purification, unless otherwise noted. Coenzyme A tri-lithium salt was 
purchased from Calbiochem. Reagents were of analytical grade or equivalent (synthesis) or 
biochemical grade. Sources of biological reagents are reported in the experimental section of the 
main paper. NMR spectra were recorded on either a JEOL GX 270 (270.05 MHz 
1
H; 67.8 MHz 
13
C) or a JEOL EX 400 (399.65 MHz 
1
H; 100.4 MHz 
13
C; 376.05 MHz) spectrometer. Spectra were 
referenced to the residual solvent peak, or externally via the solvent lock signal. Coupling constants 
(J) are reported in Hz to the nearest 0.1 Hz. Mass spectra were obtained using a VG 7070 mass 
spectrometer. Optical rotations were recorded on an Optical Activity AA-10 Automatic polarimeter 
with a path-length of 1 decimetre (1 dm). Concentrations (c) are quoted in g/100 mL. Column 
chromatography was performed using silica gel 60 (0.040-0.063 mm, Merck). Experiments were 
conducted at ambient temperature, unless otherwise stated. Solutions in organic solvents were dried 
using anhydrous sodium sulfate and solvents were evaporated under reduced pressure. 
 
Synthesis of 1-(1H-imidazol-1-yl)-tetradecan-1-one (10)  
A solution of myristic acid 9 (106 mg, 0.46 mmol) in dichloromethane (10 mL) was treated with 
solid portions of carbonyl di-imidazole (142 mg, 0.87 mmol) and the resulting reaction mixture was 
stirred under argon for 1 hour. The reaction mixture was washed with water (4 x 10 mL) and then 
dried over anhydrous sodium sulfate. Evaporation of the volatile organics gave a colourless solid 
10, 126 mg (98.5 %). 
1
H-NMR (400.04 MHz, CDCl3): δ = 0.88 (t, J = 6.5 Hz, 3H), 1.22-1.45 (m, 
20H), 1.79 (pentet, J = 7.5 Hz, 2H), 2.85 (t, J = 7.4 Hz, 2H), 7.10 (m, 1H), 7.47 (t, J = 1.4 Hz, 1H), 
8.16 (s, 1H). 
 
 
Synthesis of myristoyl-CoA (3) 
A solution of 10 (15 mg, 0.054 mmol) and coenzyme A, tri-lithium salt (14 mg, 0.018 mmol) were 
reacted in THF (1 mL) and aq. NaHCO3 solution (1 mL, 0.1 M). The reaction was stirred under 
nitrogen for 16 hours. The reaction was acidified to pH 4.5 with HCl (1M) and then washed 
repeatedly with ethyl acetate (6 x 5 mL). Freeze-drying of the aqueous layer afforded 3 as a 
colourless solid (18 mg). ESI-MS m/z calcd. for [M-H]
-
 C35H61N7O17P3S: 976.3063; found 
976.3016. 
 
Synthesis of S-4-Benzyl-3-tetradecanoyloxazolidin-2-one (11S) 
Oxalyl chloride (2.10 g, 3.2 ml, 16.7 mmol) was added slowly to a solution of myristic acid 9 (2.80 
g, 12.3 mmol) in chloroform (20 mL) at 0 ºC. The reaction was allowed to warm to room 
temperature over 1 hour. Evaporation of the volatiles in vacuo afforded the acid chloride as a 
yellow oil (~3 mL). 
n
BuLi (4.5 mL, 1.6 M, 7.2 mmol) was added dropwise to a solution of S-4-
benzyloxazolidinone (1.20 g, 6.7 mmol) in dry THF (20 mL) at -78 ºC, followed by the acid 
chloride (2 mL). Addition of the acid chloride gave a colourless precipitate, which dissolved as the 
reaction was warmed to 0 ºC over 1 hour. The reaction was stirred at this temperature for a further 
hour and then quenched by the addition of a saturated ammonium chloride solution (10 mL). The 
reaction mixture was extracted with dichloromethane (3 x 25 mL). The combined organics were 
washed with aqueous K2CO3 (20 mL, 1M) and brine (20 mL). Drying over anhydrous sodium 
sulfate and removal of the volatiles in vacuo gave the crude product as a yellow oil (3.40 g). 
Purification by column chromatography (petroleum ether/ethyl acetate, 9:1) afforded a colourless 
oil that solidified on standing to a colourless solid, 1.79 g (69.0 %). 
1
H-NMR (400.04 MHz, 
CDCl3): δ = 0.88 (t, J = 6.6 Hz, 3H), 1.20-1.44 (m, 20H), 1.69 (quintet, J = 7.2 Hz, 2H), 2.76 (dd, J 
= 9.6, 13.4 Hz, 1H), 2.93 (m, 2H), 3.30 (dd, J = 3.3, 13.4 Hz, 1H), 4.17 (m, 2H), 4.67 (m, 1H), 7.20 
(m, 2H), 7.26-7.36 (m, 3H). 
 Synthesis of R-4-Benzyl-3-tetradecanoyloxazolidin-2-one (11R) 
In a parallel synthesis 11R was obtained from myristic acid 9 (2.80 g, 12.3 mmol) and R-4-
benzyloxazolidinone (1.20 g, 6.7 mmol) as a colourless oil which solidified on standing to a 
colourless solid, 2.50 g (96 %). NMR spectra were identical to 11S. 
 
 Synthesis of 3-(S-2-Methyltetradecanoyl)-4-S-4-benzyloxazolidinone (12S) 
A solution of 11S (1.70 g, 4.40 mmol) in dry THF (5 mL) was added dropwise to a cooled (-78 ºC) 
solution of lithium bis(trimethylsilyl)amide (8.8 mL, 1.0 M in THF, 8.8 mmol), under an argon 
atmosphere. The reaction mixture was stirred for 1 hour at this temperature before methyl iodide 
(1.4 mL, 3.12g, 22 mmol) in THF (0.5 mL) at -78 ºC was added. The reaction was stirred for a 
further 3 hours at -78 ºC and then allowed to warm to 0 ºC. The reaction was quenched with 
saturated ammonium chloride (15 mL) and then extracted with dichloromethane (3 x 20 mL). The 
combined organics were washed with aqueous sodium sulfite (1M) and then dried over anhydrous 
sodium sulfate. Evaporation of the volatile organics afforded an orange oil. Purification by flash 
chromatography (petroleum ether/ethyl acetate, 20:1) gave 12S as a colourless oil, 560 mg (31.1 
%). 
1
H-NMR (400.04 MHz, CDCl3): δ = 0.88 (t, J = 6.6 Hz, 3H), 1.22 (d, J = 6.8 Hz, 3H), 1.22-
1.35 (m, 20H), 1.36-1.47 (m, 1H), 1.73 (m, 1H), 2.76 (dd, J = 9.6, 13.3 Hz, 1H), 3.27 (dd, J = 3.2, 
13.4 Hz, 1H), 3.70 (sextet, J = 6.6 Hz, 1H), 4.11-4.22 (m, 2H), 4.67 (m, 1H), 7.21 (m, 2H), 7.24-
7.36 (m, 3H). 
 
Synthesis of 3-(R-2-Methyltetradecanoyl)-4-R-4-benzyloxazolidinone (12R) 
Treatment of 11R (2.5g, 6.5 mmol) with lithium bis(trimethylsilyl)amide (8.8 mL, 1.0M in THF, 
8.8 mmol) and methyl iodide (4.56g, 2.0 mL, 32.5 mmol), as for the synthesis of 12S, afforded 12R 
as a colourless oil, 690 mg (26.4 %). NMR spectra were identical to 12S. 
Synthesis of S-2-Methyltetradecanoic acid (13S) 
A solution of 12S (550 mg, 1.4 mmol) in THF (25 mL) and water (8 mL) at 0 ºC was treated with 
hydrogen peroxide (1.2 mL, 30 %) and lithium hydroxide (70 mg, 2.8 mmol). The reaction was 
maintained at this temperature for 3 hours and then quenched with aqueous sodium sulfite (11 mL, 
1.5 M). The reaction mixture was acidified to pH 1 with HCl (1M) and then extracted with 
dichloromethane (3 x 25 mL). The combined extracts were dried over sodium sulfate and then 
evaporated in vacuo to give a colourless oil. Purification by flash chromatography (petroleum 
ether/ethyl acetate, 3:2) gave 13S as a colourless oil, 270 mg (80 %). 
1
H-NMR (400.04 MHz, 
CDCl3): δ = 0.88 (t, J = 6.6 Hz, 3H), 1.18 (d, J = 7.0 Hz, 3H), 1.22-1.37 (m, 20H), 1.37-1.48 (m, 
1H), 1.63-1.73 (m, 1H), 2.46 (sextet, J = 6.9 Hz, 1H). 
13
C-NMR (125. MHz, CDCl3): δ = 14.10, 
16.80, 22.69, 27.15, 29.48, 29.52, 29.61, 29.65, 29.68, 31.93, 39.42, 183.63. [α]D
20
 = +23.8 º (c 
0.034, methanol). 
 
Synthesis of R-2-Methyltetradecanoic acid (13R) 
Treatment of 12R (690 mg, 1.72 mmol) with lithium hydroxide (82 mg, 3.44 mmol) and hydrogen 
peroxide (1.5 mL, 30 % in H2O) as for the synthesis of 13S, afforded 13R as a colourless oil which 
solidified on standing to a colourless solid, 280 mg (67.3 %). NMR spectra were identical to 13S. 
[α]D
20
 = -23.9 º (c 0.014, methanol) 
 
Synthesis of S-1-(1H-imidazol-1-yl)-2-methyltetradecan-1-one (14S) 
A solution of 13S (100 mg, 0.41 mmol) in dichloromethane (10 mL) was treated with carbonyl di-
imidazole (133 mg, 0.82 mmol) in dichloromethane as described for the synthesis of 10. 
Evaporation of the volatile organics gave a colourless oil which solidified on standing to give a 
colourless solid 14S, 130 mg (92 %).
1
H-NMR (400.04 MHz, CDCl3): δ = 0.88 (t, J = 6.5 Hz, 3H), 
1.22-1.33 (m, 22H), 1.50-1.61 (m, 1H), 1.80-1.89 (m, 1H), 3.05 (sextet, J = 6.8 Hz, 1H), 7.11 (t, J = 
0.8 Hz, 1H), 7.49 (d, J = 1.4 Hz, 1H), 8.17 (s, 1H). 
 
Synthesis of R-1-(1H-imidazol-1-yl)-2-methyltetradecan-1-one (14R) 
As for the synthesis of 14S, 14R was prepared by treatment of 13R (100 mg, 0.41 mmol) with 
carbonyl di-imidazole (133 mg, 0.82 mmol) in dichloromethane. 14R was obtained as a colourless 
oil that solidified on standing to give a colourless solid, 115 mg (96.1 %). NMR spectra were 
identical to 14S. 
 
Synthesis of S-2-Methylmyristoyl-CoA (4S) 
A solution of 14S (12 mg, 0.041 mmol) in THF (1 mL) and coenzyme A, tri-lithium salt (11 mg, 
0.014 mmol) in THF (1 mL) and aq. NaHCO3 solution were reacted as described for the synthesis 
of 3. Freeze-drying of the aqueous layer afforded 4S as a colourless solid (14 mg). ESI-MS m/z 
calcd. for [M-H]
-
 C36H63N7O17P3S: 990.3219; found 990.3177. 
 
Synthesis of R-2-Methylmyristoyl-CoA (4R) 
In similar fashion to the preparation of 4S, 4R was obtained from the reaction of 14R (15 mg, 0.051 
mmol) and coenzyme A, tri-lithium salt (14 mg, 0.018 mmol) in THF (1 mL) and aq. NaHCO3 
solution (1 mL, 0.1 M). Freeze-drying gave 4R as a colourless solid (18 mg). ESI-MS m/z calcd. for 
[M-H]
-
 C36H63N7O17P3S: 990.3219; found 990.3176. 
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 Value ±Std. Error 95% Conf. Interval 
 Vmax 8.1547 0.9661 6.1511 to 10.1583 
 Km 38.4668 10.2782 17.1507 to 59.7828 
 
 Goodness of Fit 
 Degrees of Freedom    22 
 AICc -16.555 
 R² 0.917 
 Sum of Squares  8.920 
 Sy.x   0.637 
 Runs Test p Value 0.456 
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 Number of x values     8 
 Number of replicates 3 
 Total number of values    24 
 Number of missing values     0 
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R-2-Methylmyristoyl-CoA 4R, ACOT-1 
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Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 1.3465 0.1023 1.1324 to 1.5606 
 Km 7.7008 2.0800 3.3472 to 12.0544 
 
 Goodness of Fit 
 Degrees of Freedom    19 
 AICc -65.237 
 R² 0.822 
 Sum of Squares  0.660 
 Sy.x   0.186 
 Runs Test p Value 0.254 
 
 Data 
 Number of x values     7 
 Number of replicates 3 
 Total number of values    21 
 Number of missing values     0 
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S-2-Methylmyristoyl-CoA 4S, ACOT-1 
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Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 3.4628 0.2008 3.0464 to 3.8792 
 Km 12.4377 2.2548 7.7615 to 17.1139 
 
 Goodness of Fit 
 Degrees of Freedom    22 
 AICc -53.600 
 R² 0.935 
 Sum of Squares  1.905 
 Sy.x   0.294 
 Runs Test p Value 0.050 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    24 
 Number of missing values     0 
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±-Fenoprofenoyl-CoA 5, ACOT-1 
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 Value ±Std. Error 95% Conf. Interval 
 Vmax 12.8319 2.0165 8.6498 to 17.0140 
 Km 109.0979 27.7494 51.5481 to 166.6477 
 
 Goodness of Fit 
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 R² 0.964 
 Sum of Squares  3.602 
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 Runs Test p Value 0.237 
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±-Flurbiprofenoyl-CoA 6, ACOT-1 
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Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 11.2139 1.6125 7.8697 to 14.5582 
 Km 117.8644 26.8142 62.2541 to 173.4747 
 
 Goodness of Fit 
 Degrees of Freedom    22 
 AICc -54.182 
 R² 0.972 
 Sum of Squares  1.860 
 Sy.x   0.291 
 Runs Test p Value 0.216 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    24 
 Number of missing values     0 
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±-Ibuprofenoyl-CoA 2, ACOT-1 
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Enzyme Kinetics Nonlinear Fit Results 
 
 Notebook1 
 13/08/2011 20:04:09 
 Michaelis-Menten 
 Number of Replicates:   3 
 
 
 Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 1.5811 0.1008 1.3714 to 1.7908 
 Km 5.0993 1.2597 2.4796 to 7.7190 
 
 Goodness of Fit 
 Degrees of Freedom    21 
 AICc -65.326 
 R² 0.849 
 Sum of Squares  0.980 
 Sy.x   0.216 
 Runs Test p Value 0.158 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    23 
 Number of missing values     1 
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S-Ketoprofenoyl-CoA 7, ACOT-1 
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Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 1.2309 0.3441 0.5015 to 1.9604 
 Km 44.7606 25.5387 -9.3801 to 98.9013 
 
 Goodness of Fit 
 Degrees of Freedom    16 
 AICc -57.669 
 R² 0.664 
 Sum of Squares  0.476 
 Sy.x   0.173 
 Runs Test p Value 0.213 
 
 Data 
 Number of x values     7 
 Number of replicates 3 
 Total number of values    18 
 Number of missing values     3 
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S-Naproxenoyl-CoA 8, ACOT-1 
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Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 0.5278 2.638e-2 0.4731 to 0.5825 
 Km 2.7646 0.6042 1.5116 to 4.0177 
 
 Goodness of Fit 
 Degrees of Freedom    22 
 AICc -123.839 
 R² 0.823 
 Sum of Squares  0.102 
 Sy.x 6.812e-2 
 Runs Test p Value 0.076 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    24 
 Number of missing values     0 
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Myristoyl-CoA 3, ACOT-2 
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Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 3.2003 0.1581 2.8724 to 3.5282 
 Km 15.4965 2.2602 10.8090 to 20.1840 
 
 Goodness of Fit 
 Degrees of Freedom    22 
 AICc -70.983 
 R² 0.960 
 Sum of Squares  0.924 
 Sy.x   0.205 
 Runs Test p Value 0.443 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    24 
 Number of missing values     0 
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R-2-Methylmyristoyl-CoA 4R, ACOT-2 
 
 
Direct Linear Plot
Apparent K
m
-100 -50 0 50 100
A
p
p
a
re
n
t 
V
m
a
x
0
1
2
3
4
Michaelis-Menten
[Substrate] (µM)
0 20 40 60 80 100 120
R
a
te
 (
n
m
o
l.
-1
m
in
.-
1
m
g
-1
)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 1.0804 8.920e-2 0.8949 to 1.2659 
 Km 2.4503 0.9447 0.4857 to 4.4149 
 
 Goodness of Fit 
 Degrees of Freedom    21 
 AICc -61.393 
 R² 0.637 
 Sum of Squares  1.162 
 Sy.x   0.235 
 Runs Test p Value 0.447 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    23 
 Number of missing values     1 
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S-2-Methylmyristoyl-CoA 4S, ACOT-2 
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Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 5.7688 0.3536 5.0354 to 6.5022 
 Km  31.7988 4.6683 22.1171 to 41.4805 
 
 Goodness of Fit 
 Degrees of Freedom    22 
 AICc -56.794 
 R² 0.971 
 Sum of Squares  1.668 
 Sy.x   0.275 
 Runs Test p Value 0.387 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    24 
 Number of missing values     0 
 
 
   
Lineweaver-Burk
1/[Substrate] (µM)
-0.2 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
1
/R
a
te
 1
/(
n
m
o
l.
-1
m
in
.-
1
m
g
-1
)
1
2
3
4
5
6
 
 
Residuals
[Substrate] (µM)
0 20 40 60 80 100 120
R
e
s
id
u
a
ls
 (
n
m
o
l.
-1
m
in
.-
1
m
g
-1
)
-0.6
-0.4
-0.2
0.0
0.2
0.4
0.6
 
 
 
 
 
 
±-Fenoprofenoyl-CoA 5, ACOT-2 
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Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 9.5307 0.8409 7.7867 to 11.2747 
 Km 45.0815 8.5257 27.3998 to 62.7631 
 
 Goodness of Fit 
 Degrees of Freedom    22 
 AICc -30.431 
 R² 0.959 
 Sum of Squares  5.003 
 Sy.x   0.477 
 Runs Test p Value 0.350 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    24 
 Number of missing values     0 
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 ±-Flurbiprofenoyl-CoA 6, ACOT-2 
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Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 9.7130 1.1102 7.3319 to 12.0941 
 Km 30.5008 8.4578 12.3604 to 48.6413 
 
 Goodness of Fit 
 Degrees of Freedom    14 
 AICc -4.180 
 R² 0.933 
 Sum of Squares  7.474 
 Sy.x   0.731 
 Runs Test p Value 0.277 
 
 Data 
 Number of x values     8 
 Number of replicates 2 
 Total number of values    16 
 Number of missing values     0 
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±-Ibuprofenoyl-CoA 2, ACOT-2 
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Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 3.2478 0.5254 2.1481 to 4.3475 
 Km 33.7370 12.8536 6.8336 to 60.6403 
 
 Goodness of Fit 
 Degrees of Freedom    19 
 AICc -34.474 
 R² 0.840 
 Sum of Squares  2.858 
 Sy.x   0.388 
 Runs Test p Value 0.199 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    21 
 Number of missing values     3 
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 S-Ketoprofenoyl-CoA 7, ACOT-2 
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Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 0.7170 7.780e-2 0.5502 to 0.8839 
 Km 9.4655 3.4336 2.1011 to 16.8299 
 
 Goodness of Fit 
 Degrees of Freedom    14 
 AICc -65.768 
 R² 0.754 
 Sum of Squares  0.159 
 Sy.x   0.107 
 Runs Test p Value 0.501 
 
 Data 
 Number of x values     8 
 Number of replicates 2 
 Total number of values    16 
 Number of missing values     0 
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S-Naproxenoyl-CoA 8, ACOT-2 
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Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 0.5242 3.025e-2 0.4593 to 0.5891 
 Km 1.8480 0.5116 0.7506 to 2.9453 
 
 Goodness of Fit 
 Degrees of Freedom    14 
 AICc -79.194 
 R² 0.720 
 Sum of Squares 6.876e-2 
 Sy.x 7.008e-2 
 Runs Test p Value 0.060 
 
 Data 
 Number of x values     8 
 Number of replicates 2 
 Total number of values    16 
    Number of missing values          0 
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Figure S1: Sequence alignment of human ACOT-1 and ACOT-2 
 
ACOT-1          ------------------------------------------------------------ 
ACOT-2          MSNKLLSPHPHSVVLRSEFKMASSPAVLRASRLYQWSLKSSAQFLGSPQLRQVGQIIRVP 
                                                                             
 
ACOT-1          --MAATLILEPAGRCCWDEPVRIAVRGLAPEQPVTLRASLRDEKGALFQAHARYRADTLG 
ACOT-2          ARMAATLILEPAGRCCWDEPVRIAVRGLAPEQPVTLRASLRDEKGALFQAHARYRADTLG 
                  ********************************************************** 
 
ACOT-1          ELDLERAPALGGSFAGLEPMGLLWALEPEKPLVRLVKRDVRTPLAVELEVLDGHDPDPGR 
ACOT-2          ELDLERAPALGGSFAGLEPMGLLWALEPEKPLVRLVKRDVRTPLAVELEVLDGHDPDPGR 
                ************************************************************ 
 
ACOT-1          LLCRVRHERYFLPPGVRREPVRAGRVRGTLFLPPEPGPFPGIVDMFGTGGGLLEYRASLL 
ACOT-2          LLCQTRHERYFLPPGVRREPVRVGRVRGTLFLPPEPGPFPGIVDMFGTGGGLLEYRASLL 
                ***:.*****************.************************************* 
 
ACOT-1          AGKGFAVMALAYYNYEDLPKTMETLHLEYFEEAVNYLLSHPEVKGPGVGLLGISKGGELC 
ACOT-2          AGKGFAVMALAYYNYEDLPKTMETLHLEYFEEAMNYLLSHPEVKGPGVGLLGISKGGELC 
                *********************************:************************** 
 
ACOT-1          LSMASFLKGITAAVVINGSVANVGGTLRYKGETLPPVGVNRNRIKVTKDGYADIVDVLNS 
ACOT-2          LSMASFLKGITAAVVINGSVANVGGTLRYKGETLPPVGVNRNRIKVTKDGYADIVDVLNS 
                ************************************************************ 
 
ACOT-1          PLEGPDQKSFIPVERAESTFLFLVGQDDHNWKSEFYANEACKRLQAHGRRKPQIICYPET 
ACOT-2          PLEGPDQKSFIPVERAESTFLFLVGQDDHNWKSEFYANEACKRLQAHGRRKPQIICYPET 
                ************************************************************ 
 
ACOT-1          GHYIEPPYFPLCRASLHALVGSPIIWGGEPRAHAMAQVDAWKQLQTFFHKHLGGREGTIP 
ACOT-2          GHYIEPPYFPLCRASLHALVGSPIIWGGEPRAHAMAQVDAWKQLQTFFHKHLGGHEGTIP 
                ******************************************************:***** 
 
ACOT-1          SKV 
ACOT-2          SKV 
                *** 
 
Figure S1: Primary sequence alignment of human ACOT-1 (A1L172) and ACOT-2 (P49753). 
Sequences were obtained from http://www.uniprot.org/ and aligned with ClusterW 
(http://www.ch.embnet.org/software/ClustalW.html) with default parameters. Active site catalytic 
triad residues are shown in green.  
 
